NASDAQ:NDRA ENDRA Life Sciences (NDRA) Stock Price, News & Analysis $5.31 +0.13 (+2.51%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$5.38 +0.07 (+1.39%) As of 06/23/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About ENDRA Life Sciences Stock (NASDAQ:NDRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ENDRA Life Sciences alerts:Sign Up Key Stats Today's Range$4.80▼$5.3150-Day Range$4.19▼$6.4052-Week Range$2.96▼$11.96Volume12,146 shsAverage Volume16,210 shsMarket Capitalization$6.74 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview ENDRA Life Sciences, Inc. (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies. ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems. Using patented algorithms and specialized hardware, the system captures thermoacoustic signals generated when tissue is exposed to low-power microwave pulses. These signals enable clinicians to visualize temperature distributions during procedures such as radiofrequency ablation, microwave ablation and high-intensity focused ultrasound. The company collaborates with hospitals, academic research centers and medical device partners to conduct preclinical and clinical studies that validate the performance and utility of TAEUS technology. The company holds a growing portfolio of issued and pending patents across the United States, Europe and Asia, and it is advancing toward broader regulatory clearances and international market entry. ENDRA’s leadership team is led by President and Chief Executive Officer David Kaiss, who brings two decades of experience in medical device development, regulatory affairs and commercialization. Under his direction, the company has expanded its R&D capabilities, strengthened manufacturing partnerships and established key distribution channels to support future product launches.AI Generated. May Contain Errors. Read More ENDRA Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreNDRA MarketRank™: ENDRA Life Sciences scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingENDRA Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialENDRA Life Sciences has a consensus price target of $25.00, representing about 370.8% upside from its current price of $5.31.Amount of Analyst CoverageENDRA Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about ENDRA Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ENDRA Life Sciences are expected to grow in the coming year, from ($4.11) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ENDRA Life Sciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.73% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently decreased by 39.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ENDRA Life Sciences this week, compared to 2 articles on an average week.Search Interest1 people have searched for NDRA on MarketBeat in the last 30 days. MarketBeat Follows4 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by Institutions1.19% of the stock of ENDRA Life Sciences is held by institutions.Read more about ENDRA Life Sciences' insider trading history. Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NDRA Stock News HeadlinesAnalyzing NeuroPace (NASDAQ:NPCE) and ENDRA Life Sciences (NASDAQ:NDRA)June 19, 2026 | americanbankingnews.comNDRA Share News TodayJune 15, 2026 | uk.investing.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all. | Porter & Company (Ad)ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 18, 2026 | finance.yahoo.comENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 18, 2026 | businesswire.comENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and ReproducibilityMay 14, 2026 | finance.yahoo.comENDRA Life Sciences (NDRA) price target decreased by 10.00% to 27.54April 15, 2026 | msn.comENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | businesswire.comSee More Headlines NDRA Stock Analysis - Frequently Asked Questions How have NDRA shares performed this year? ENDRA Life Sciences' stock was trading at $4.53 at the start of the year. Since then, NDRA shares have increased by 17.2% and is now trading at $5.31. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its earnings results on Friday, May, 15th. The company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.14. When did ENDRA Life Sciences' stock split? ENDRA Life Sciences's stock reverse split on Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did ENDRA Life Sciences IPO? ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO. How do I buy shares of ENDRA Life Sciences? Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL). Company Calendar Last Earnings5/15/2026Today6/23/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NDRA's financial health is in the Green zone, according to TradeSmith. NDRA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NDRA CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for ENDRA Life Sciences$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+370.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.03 million Net MarginsN/A Pretax MarginN/A Return on Equity-433.64% Return on Assets-204.58% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book2.77Miscellaneous Outstanding Shares1,270,000Free Float1,143,000Market Cap$6.74 million OptionableNot Optionable Beta-0.04 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:NDRA) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NDRA Stock Alerts